Sign In
Buy ABCM
$23.99
+0 (+0%)
At Close: Mar 04, 2024
Abcam: A Promising Business Model In The Drug Industry
09:56am, Friday, 09'th Jul 2021
I will outline the history of drug development. Information for the Abcam business model will be outlined for my readers.
Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients
08:00am, Tuesday, 22'nd Jun 2021
SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the bo
Abcam and MEDx extend precision medicine strategic partnership
05:00am, Monday, 12'th Apr 2021
CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine
Avacta Announces Distribution Agreement With ABCAM plc
06:21am, Tuesday, 06'th Apr 2021
CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleas
5 Companies Trading Below Historical Low Price-Book as of March
05:56pm, Friday, 26'th Mar 2021
Stocks with high business profitability and price-book ratios near 10-year lows
Abcam Wins Industry Awards from CiteAb
07:49am, Wednesday, 24'th Mar 2021
CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Res
Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript
02:40pm, Monday, 08'th Mar 2021
Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript
8.3% constant currency revenue growth in H1 as customers gradually return to labs
07:00am, Monday, 08'th Mar 2021
CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science rese
Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector
04:00am, Thursday, 04'th Mar 2021
CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in Chi
Abcam to Report Interim Results on Monday, March 8, 2021
02:00am, Friday, 26'th Feb 2021
CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will r
Abcam to present at the 2021 SVB Leerink Global Healthcare Conference
07:00am, Wednesday, 17'th Feb 2021
CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global H
Abcam Plc Appointment of Non-Executive Directors
02:00am, Thursday, 28'th Jan 2021
CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce th
Abcam: An Attractive, Profitable Medtech But Pricy
08:15am, Monday, 18'th Jan 2021
Abcam has a strong position in the niche of supplies for antibody research. It is profitable, dividend paying, and continues to grow well.
